By fluorescent confocal microscopy, we observed that the mice that received combination treatment cleared the tumor burden and demonstrated loss of both EGFRvIII and HER2 expressing cells, while EGFRvIII-DBTE-treated mice showed HER2 expression and conversely HER2-DBTE-treated mice showed continued EGFRvIII expression in the tumor sections (Figure 8G). Here, ERBB2 is linked to neoplasm.